GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » Cyclically Adjusted Price-to-FCF

Daxor (DXR) Cyclically Adjusted Price-to-FCF : 21.93 (As of Apr. 27, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Daxor Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), Daxor's current share price is $9.65. Daxor's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 was $0.44. Daxor's Cyclically Adjusted Price-to-FCF for today is 21.93.

The historical rank and industry rank for Daxor's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

DXR' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 17.93   Med: 46.91   Max: 465.33
Current: 22

During the past 13 years, Daxor's highest Cyclically Adjusted Price-to-FCF was 465.33. The lowest was 17.93. And the median was 46.91.

DXR's Cyclically Adjusted Price-to-FCF is ranked better than
72.93% of 229 companies
in the Medical Devices & Instruments industry
Industry Median: 42.33 vs DXR: 22.00

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Daxor's adjusted free cash flow per share data of for the fiscal year that ended in Dec23 was $-0.789. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.44 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Daxor Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Daxor's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daxor Cyclically Adjusted Price-to-FCF Chart

Daxor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 370.51 41.57 21.89

Daxor Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 370.51 - 41.57 - 21.89

Competitive Comparison of Daxor's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, Daxor's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daxor's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Daxor's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Daxor's Cyclically Adjusted Price-to-FCF falls into.



Daxor Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Daxor's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=9.65/0.44
=21.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daxor's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Daxor's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=-0.789/129.4194*129.4194
=-0.789

Current CPI (Dec23) = 129.4194.

Daxor Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -0.079 99.070 -0.103
201512 4.821 99.792 6.252
201612 0.416 101.863 0.529
201712 -0.311 104.011 -0.387
201812 -0.352 105.998 -0.430
201912 0.831 108.420 0.992
202012 -0.622 109.897 -0.732
202112 -0.683 117.630 -0.751
202212 -0.188 125.222 -0.194
202312 -0.789 129.419 -0.789

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Daxor  (NAS:DXR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Daxor Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Daxor's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Daxor (DXR) Business Description

Traded in Other Exchanges
Address
109 Meco Lane, Oak Ridge, TN, USA, 37830
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Executives
Robert J Michel officer: CHIEF FINANCIAL OFFICER C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh director 71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers director DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer director 2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson officer: V.P./BUSINESS DEVELOPMENT 180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh director, officer: CHIEF SCIENTIFIC OFFICER DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh officer: President 615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh other: FOUNDER 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan officer: Corporate Secretary 259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe director 6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens director 200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson director P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom officer: Vice President 3244 BLACK FOX ROAD, WASHBURN TN 37888

Daxor (DXR) Headlines

From GuruFocus

Daxor Corporation Announces Proposed Underwritten Public Offering

By sperokesalga sperokesalga 05-19-2023